We can thank Biosciencetechnology.com for this report about continuing genetic research which may help treat some non-Hodgkin’s lymphoma patients:
New mutation linked to non-Hodgkin’s lymphoma
Featured In: Disease Research
By EurekAlert – Tuesday, November 2, 2010
Some patients with non-Hodgkin lymphoma (NHL)—a cancer of B cells—harbor a particular mutation in the gene encoding the receptor for B cell activating factor (BAFF), according to a paper published online on November 1 in the Journal of Experimental Medicine (www.jem.org). BAFF, a soluble protein needed for B cell survival and maturation, is elevated in the blood of some NHL patients and is associated with poor prognosis.
This BAFF-R mutation, identified by a team led by Anne Novak and Gail Bishop, generates a receptor that transmits stronger than normal signals, thus boosting B cell function.
Although present in fewer than 10% of the tumors analyzed in the study, this mutation provides further evidence of the importance of BAFF signaling in this dangerous malignancy.
This science is so complex it blows my mind! But with the help of very powerful computers, researchers are beginning to successfully link all of these individual findings together. Should eventually help many cancer patients to be treated more successfully. Not a cure, but the next step.
Feel good and keep smiling! Pat